Lenvatinib and sorafenib for treating advanced hepatocellular carcinoma

Published on 04 Jan 2022
Last Updated on 04 Jan 2022

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Sorafenib 200 mg tablet; and

• Lenvatinib 4 mg and 10 mg capsules

for treating advanced unresectable hepatocellular carcinoma in patients with adequate liver function as assessed by the Child-Pugh scoring system.

Subsidy status

Sorafenib 200 mg tablet is recommended for inclusion on the MOH Standard Drug List (SDL) and lenvatinib 4 mg and 10 mg capsules are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication when used according to HSA-recommended dosing regimens.

SDL subsidy for sorafenib will be implemented from 4 January 2022, while MAF assistance for lenvatinib will be implemented from 1 September 2022.

Clinical indications, subsidy class and MediShield Life claim limits for both drugs are provided in the Annex.

Lenvatinib and sorafenib for treating advanced HCC (4 Jan 2022) [PDF, 129 KB]

PES Treatments for advanced hepatocellular carcinoma (Updated 19 December 2022) [PDF, 86 KB]